	US 12,454,561 B2
	Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
Robert E. Sobol, Houston, TX (US); Kerstin B. Menander, Houston, TX (US); Dora Wiederhold, Houston, TX (US); and Sunil Chada, Houston, TX (US)
Assigned to Multivir Inc., Houston, TX (US)
Appl. No. 15/733,619
Filed by MULTIVIR INC., Houston, TX (US)
PCT Filed Mar. 19, 2019, PCT No. PCT/US2019/022985 § 371(c)(1), (2) Date Sep. 17, 2020, PCT Pub. No. WO2020/036635, PCT Pub. Date Feb. 20, 2020.
Claims priority of provisional application 62/803,887, filed on Feb. 11, 2019.
Claims priority of provisional application 62/645,022, filed on Mar. 19, 2018.
Prior Publication US 2021/0094991 A1, Apr. 1, 2021
Int. Cl. C07K 14/47 (2006.01); A61K 35/768 (2015.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C12N 15/86 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)

CPC C07K 14/4746 (2013.01) [A61K 35/768 (2013.01); A61K 48/005 (2013.01); A61P 35/00 (2018.01); C07K 14/54 (2013.01); C12N 15/86 (2013.01); A61K 9/0019 (2013.01); A61K 45/06 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/24143 (2013.01)]

23 Claims

1. A method of treating cancer in a subject comprising administering an effective amount of (1) a nucleic acid encoding p53 and/or a nucleic acid encoding MDA-7, (2) at least one agonist which preferentially binds to CD122/CD132, wherein the agonist is selected from the group consisting of an IL-2/anti-IL-2 immune complex, an IL-15/anti-IL-15 immune complex, an IL-15/IL-15 Receptor α-IgG1-Fc (IL-15/IL-15Rα-IgG1-Fc) immune complex, PEGylated IL-2, PEGylated IL-15, IL-2 mutein, IL-15 mutein, and IL-15 mutant bound to an IL-15 receptor α/IgG1 Fc fusion protein, and (3) at least one immune checkpoint inhibitor to the subject; and wherein the immune checkpoint inhibitor is an inhibitor of PD-1 or PD-L1.